An official website of the United States government
The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before
sharing sensitive information, make sure you’re on a federal
government site.
The site is secure.
The https:// ensures that you are connecting to the
official website and that any information you provide is encrypted
and transmitted securely.
This cohort study evaluates the sociodemographic characteristics of patients with urachal cancer, cancer treatments, and the association of patient characteristics with overall survival.
Conflict of Interest Disclosures: Dr Kalebasty reported receiving personal fees for participating on a speakers’ bureau and receiving research funds from Exelixis, AstraZeneca, Bayer, Pfizer, Novartis, Genentech/Roche, Bristol Myers Squibb, EMD Serono, Immunomedics, Gilead Sciences, AVEO, Janssen, Eisai, Amgen, Merck & Co, Seattle Genetics/Astellas, and Myovant Sciences; receiving personal fees for participating on a speakers’ bureau from Sanofi; receiving research funding from Macrogenics, BeyondSpring Pharmaceuticals, BioClin Therapeutics, Clovis Oncology, Bavarian Nordic, and Epizyme; receiving personal fees for travel from Genentech, Prometheus, Astellas Medivation, Janssen, Eisai, Bayer, Pfizer, Novartis, Exelixis, and AstraZeneca; and owning stock in ECOM Medical outside the submitted work. No other disclosures were reported.
References
Ashley RA, Inman BA, Sebo TJ, et al. . Urachal carcinoma: clinicopathologic features and long-term outcomes of an aggressive malignancy. Cancer. 2006;107(4):712-720. doi:10.1002/cncr.22060
-
DOI
-
PubMed
Mennitto A, Vernieri C, Procopio G. Urachal carcinoma: towards a precision medicine. Transl Cancer Res. 2016;5(7). doi:10.21037/11280
-
DOI
Hamilou Z, North S, Canil C, et al. . Management of urachal cancer: a consensus statement by the Canadian Urological Association and Genitourinary Medical Oncologists of Canada. Can Urol Assoc J. 2020;14(3):E57-E64.
-
PMC
-
PubMed
